OBJECTIVE: To analyse intensity of treatment of high-risk patients with non-ST elevation acute coronary syndromes (NSTEACS) included in the DESCARTES (Descripción del Estado de los Sindromes Coronarios Agudos en un Registro Temporal Español) registry. PATIENTS AND SETTING: Patients with NSTEACS (n = 1877) admitted to 45 randomly selected Spanish hospitals in April and May 2002 were studied. DESIGN: Patients with ST segment depression and troponin rise were considered high risk (n = 478) and were compared with non-high risk patients (n = 1399). RESULTS: 46.9% of high-risk patients versus 39.5% of non-high-risk patients underwent angiography (p = 0.005), 23.2% versus 18.8% (p = 0.038) underwent percutaneous revascularisation, and 24.9% versus 7.4% (p < 0.001) were given glycoprotein IIb/IIIa inhibitor. In-hospital and six-month mortality were 7.5% versus 1.1% and 17% versus 4.6% (p < 0.001), respectively. A treatment score (> or = 4, 2-3 and < 2) was defined according to the number of class I interventions recommended in clinical guidelines: aspirin, clopidogrel, beta blockers, angiotensin-converting enzyme inhibitors, statins and revascularisation. Independent predictors of six-month mortality were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04 to 1.10, p < 0.001), diabetes (OR 1.92, 95% CI 1.14 to 3.22, p = 0.014), previous cardiovascular disease (OR 4.17, 95% CI 1.63 to 10.68, p = 0.003), high risk (OR 2.20, 95% CI 1.30 to 3.71, p = 0.003) and treatment score < 2 versus > or = 4 (OR 2.87, 95% CI 1.27 to 6.52, p = 0.012). CONCLUSIONS: Class I recommended treatments were underused in high-risk patients in the DESCARTES registry. This undertreatment was an independent predictor of death of patients with an acute coronary syndrome.
OBJECTIVE: To analyse intensity of treatment of high-risk patients with non-ST elevation acute coronary syndromes (NSTEACS) included in the DESCARTES (Descripción del Estado de los Sindromes Coronarios Agudos en un Registro Temporal Español) registry. PATIENTS AND SETTING:Patients with NSTEACS (n = 1877) admitted to 45 randomly selected Spanish hospitals in April and May 2002 were studied. DESIGN:Patients with ST segment depression and troponin rise were considered high risk (n = 478) and were compared with non-high risk patients (n = 1399). RESULTS: 46.9% of high-risk patients versus 39.5% of non-high-risk patients underwent angiography (p = 0.005), 23.2% versus 18.8% (p = 0.038) underwent percutaneous revascularisation, and 24.9% versus 7.4% (p < 0.001) were given glycoprotein IIb/IIIa inhibitor. In-hospital and six-month mortality were 7.5% versus 1.1% and 17% versus 4.6% (p < 0.001), respectively. A treatment score (> or = 4, 2-3 and < 2) was defined according to the number of class I interventions recommended in clinical guidelines: aspirin, clopidogrel, beta blockers, angiotensin-converting enzyme inhibitors, statins and revascularisation. Independent predictors of six-month mortality were age (odds ratio (OR) 1.07, 95% confidence interval (CI) 1.04 to 1.10, p < 0.001), diabetes (OR 1.92, 95% CI 1.14 to 3.22, p = 0.014), previous cardiovascular disease (OR 4.17, 95% CI 1.63 to 10.68, p = 0.003), high risk (OR 2.20, 95% CI 1.30 to 3.71, p = 0.003) and treatment score < 2 versus > or = 4 (OR 2.87, 95% CI 1.27 to 6.52, p = 0.012). CONCLUSIONS: Class I recommended treatments were underused in high-risk patients in the DESCARTES registry. This undertreatment was an independent predictor of death of patients with an acute coronary syndrome.
Authors: M Heras; A Fernández Ortiz; J A Gómez Guindal; J A Iriarte; R M Lidón; F Pérez Gómez; I Roldán Journal: Rev Esp Cardiol Date: 1999-10 Impact factor: 4.753
Authors: Michel E Bertrand; Maarten L Simoons; Keith A A Fox; Lars C Wallentin; Christian W Hamm; Eugene McFadden; Pim J De Feyter; Giuseppe Specchia; Witold Ruzyllo Journal: Eur Heart J Date: 2002-12 Impact factor: 29.983
Authors: E Magnus Ohman; Matthew T Roe; Sidney C Smith; Ralph G Brindis; Robert H Christenson; Robert A Harrington; W Brian Gibler; Eric D Peterson Journal: Am Heart J Date: 2004-11 Impact factor: 4.749
Authors: L López Bescós; A Fernández-Ortiz; H Bueno Zamora; I Coma Canella; R M Lidón Corbi; A Cequier Fillat; J Tuñón Fernández; R Masiá Martorell; J Marrugat de la Iglesia; M Palencia Pérez; A Loma-Osorio; J Bayón Fernández; F Arós Borau Journal: Rev Esp Cardiol Date: 2000-06 Impact factor: 4.753
Authors: Eric D Peterson; Charles V Pollack; Matthew T Roe; Lori S Parsons; Katherine A Littrell; John G Canto; Hal V Barron Journal: J Am Coll Cardiol Date: 2003-07-02 Impact factor: 24.094
Authors: Matteo Nicola Dario Di Minno; Anna Guida; Marina Camera; Susanna Colli; Giovanni Di Minno; Elena Tremoli Journal: Ann Med Date: 2011-08-05 Impact factor: 4.709
Authors: Josien Engel; Judith M Poldervaart; Ineke van der Wulp; Johannes B Reitsma; Martine C de Bruijne; Jeroen J H Bunge; Maarten J Cramer; Wouter J Tietge; Ruben Uijlings; Cordula Wagner Journal: BMJ Open Date: 2017-01-19 Impact factor: 2.692
Authors: Marcus D Flather; Jean Booth; Daphne Babalis; Hector Bueno; Philippe G Steg; Grzegorz Opolski; Filippo Ottani; Jacques Machecourt; Alfredo Bardaji; Mats Bojestig; Anthony R Brady; Bertil Lindahl Journal: Trials Date: 2010-01-14 Impact factor: 2.279
Authors: Jean-Pierre Bassand; Gabriele Accetta; Wael Al Mahmeed; Ramon Corbalan; John Eikelboom; David A Fitzmaurice; Keith A A Fox; Haiyan Gao; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Karen Pieper; Alexander G G Turpie; Martin van Eickels; Freek W A Verheugt; Ajay K Kakkar Journal: PLoS One Date: 2018-01-25 Impact factor: 3.240